相关实验视频
Updated: Sep 16, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
在1型糖尿病中保护隐私的血糖管理:开发和验证多目标联合增强学习框架
1Computer Science Department, North Dakota State University, 1320 Albrecht Blvd, Fargo, ND, 58105, United States, 1 7012319662.
JMIR diabetes
|July 4, 2025
概括
这项研究介绍了PRIMO-FRL,这是一种用于糖尿病管理的新型隐私保护人工智能框架,可以消除低血糖并改善范围内的时间. 联合强化学习方法增强了血糖控制,同时保护了患者数据的隐私.
科学领域:
- 医疗保健中的人工智能
- 机器学习用于糖尿病管理管理
- 强化学习用于血糖控制
背景情况:
- 有效的糖尿病管理需要精确的血糖控制,以防止低血糖和高血糖.
- 现有的机器学习 (ML) 和强化学习 (RL) 方法往往难以平衡竞争的目标,例如尽量减少胰岛素使用和减少血糖变化.
- 当前系统中的集中数据处理引发了对敏感健康数据的隐私问题,突出了对分散的,保护隐私的解决方案的需求.
研究的目的:
- 开发和验证PRIMO-FRL (使用联合强化学习进行个性化多目标血糖管理的隐私保护强化学习).
- 优化临床目标,包括最大化范围内的时间 (TIR),减少低血糖和高血糖,并最大限度地降低血糖风险.
- 通过创新的联合强化学习框架,确保患者的隐私.
主要方法:
- 开发了PRIMO-FRL,结合多目标奖励塑造来实现葡萄糖稳定性,胰岛素效率和风险降低的动态平衡.
- 通过FDA批准的UVA/Padova模拟器,通过30名患者 (儿童,青少年,成年人) 的模拟数据训练和测试该模型.
- 进行了对最先进的RL和ML模型进行比较分析,使用TIR,低血糖,高血糖和血糖风险等指标.
主要成果:
- PRIMO-FRL实现了总体TIR的76.54%,成年人显示的最高为81.48%.
- 该框架成功地消除了所有年龄组的低血糖 (0.0%低于70毫克/分升),明显优于现有方法.
- 成年人表现出对轻度高血糖的最佳控制 (18.52%),该方法始终降低了血糖风险得分,表明安全性得到改善.
结论:
- PRIMO-FRL展示了转型潜力,作为一种保护隐私的方法,使用联合强化学习来进行个性化的血糖管理.
- 该框架消除低血糖,改善TIR,并通过分散模型培训来保护数据隐私,解决集中系统的局限性.
- PRIMO-FRL为现实世界糖尿病护理提供了可扩展,安全和临床可行的解决方案,为在敏感医疗环境中保护隐私的AI铺平了道路.
相关概念视频
Diabetes: Management and Pharmacotherapy
408
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
408
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
Hypoglycemia and Glucagon
349
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
349
Glucagon-like Receptor Agonists
431
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
431
Glucose Homeostasis: Regulation of Blood Glucose
2.6K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
2.6K

